Technical Analysis for NCNA - NuCana plc

Grade Last Price % Change Price Change
grade D 12.93 -5.27% -0.72
NCNA closed down 5.27 percent on Tuesday, April 23, 2019, on 19 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical NCNA trend table...

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Wide Bands Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
50 DMA Resistance Bearish -5.27%
Lower Bollinger Band Walk Weakness -5.27%
Wide Bands Range Expansion -5.27%
Oversold Stochastic Weakness -5.27%

Older signals for NCNA ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The Company utilizes its ProTide technology to develop medicines to overcome cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline of products includes Acelarin, NUC-3373 and NUC-7738. Acelarin is a nucleotide analog and is a ProTide transformation of gemcitabine for the treatment of cancer. The Company is evaluating Acelarin in four clinical trials across several solid tumor indications. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil for the treatment of a wide range of cancers. NUC-3373 is in a Phase I trial for the potential treatment of a wide range of solid tumor cancers. NUC-7738 is a ProTide transformation of cordycepin, a novel nucleoside analog.
Is NCNA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 32.0
52 Week Low 10.37
Average Volume 66,336
200-Day Moving Average 18.1518
50-Day Moving Average 14.3136
20-Day Moving Average 15.7665
10-Day Moving Average 14.861
Average True Range 1.3377
ADX 22.67
+DI 18.3211
-DI 23.3602
Chandelier Exit (Long, 3 ATRs ) 15.2669
Chandelier Exit (Short, 3 ATRs ) 16.9131
Upper Bollinger Band 18.5603
Lower Bollinger Band 12.9727
Percent B (%b) -0.01
BandWidth 35.439698
MACD Line -0.3896
MACD Signal Line 0.124
MACD Histogram -0.5136
Fundamentals Value
Market Cap 411.32 Million
Num Shares 31.8 Million
EPS -0.40
Price-to-Earnings (P/E) Ratio -32.33
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 14.43
Resistance 3 (R3) 14.60 14.26 14.18
Resistance 2 (R2) 14.26 13.88 14.18 14.10
Resistance 1 (R1) 13.60 13.65 13.43 13.43 14.01
Pivot Point 13.26 13.26 13.18 13.18 13.26
Support 1 (S1) 12.60 12.88 12.43 12.43 11.85
Support 2 (S2) 12.26 12.65 12.18 11.76
Support 3 (S3) 11.60 12.26 11.68
Support 4 (S4) 11.43